Intercell Q1 net loss declines 19.3 pct to 7.1 mln eur |
|
|
|
Published
:
Mon, 14 May 2007 07:18
|
VIENNA (Thomson Financial) - Austrian vaccine company Intercell AG said net loss for the first quarter narrowed 19.3 pct year-on-year to 7.1 mln eur thanks to an increase in revenues and a decrease in the share of loss of associated companies.Revenue for the first quarter grew to 1.5 mln eur, compared with 0.3 mln in the first quarter of 2006, as a result of higher grant income and higher revenue from existing partnerships and licensing agreements with pharmaceutical companies, Intercell said in a statement.Intercell said research and development expenses in the first three months increased 8.8 pct to 7.4 mln eur year-on-year.The US market launch of its Japanese Encephalitis vaccine remains on track for early 2008 and will be brought to market in Europe in late 2008, Intercell said.fiona.flanagan@thomson.comff/amCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
Print this Story
Intercell's/SSI's new vaccine proved safe in phase I clinical trial 